Drug Profile
CM 728
Alternative Names: CM-728Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator CEAMED
- Class Antineoplastics; Quinones; Small molecules
- Mechanism of Action Apoptosis stimulants; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Spain (PO)